Clinical Trials for Retinal Disorders

Currently registered clinical trials for Retinal Disorders from ClinicalTrials.gov. 21 recruiting, 50 total studies.

This content is for informational purposes only. Always consult a healthcare professional.

Source: ClinicalTrials.gov — U.S. National Library of Medicine — A database of privately and publicly funded clinical studies conducted around the world (U.S. National Library of Medicine, public domain).

This page lists clinical trials related to Retinal Disorders from the ClinicalTrials.gov database.

Trial Summary

  • Total studies: 50
  • Recruiting: 21
  • Active, not recruiting: 10
  • Completed: 8
  • Other: 11

Results are refreshed periodically and may not reflect the most current information available from ClinicalTrials.gov.

Recruiting Trials

StatusRecruiting
PhaseN/A
SponsorNational Human Genome Research Institute (NHGRI)
Enrollment5000
Study TypeOBSERVATIONAL
ConditionsFamilial Mediterranean Fever (FMF); Autoinflammation; Periodic Fever; Fever; Genetic Diseases

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases.

The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) r…

StatusRecruiting
PhaseN/A
SponsorNational Cancer Institute (NCI)
Enrollment6035
Study TypeOBSERVATIONAL
ConditionsSarcoma; Endocrine Tumors; Neuroblastoma; Retinoblastoma; Renal Cancer

Background:

- Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, additional samples will be collected from children and adults who have been diagnosed with common childh…

NCT02617966 — Rod and Cone Mediated Function in Retinal Disease

StatusRecruiting
PhaseN/A
SponsorNational Eye Institute (NEI)
Enrollment500
Study TypeOBSERVATIONAL
ConditionsRetinal Degeneration; Retinitis Pigmentosa; Stargardt’s Disease

Background:

Retinal diseases cause the loss of rod and cone photoreceptors. Symptoms include vision loss and night blindness. Researchers want to learn about rod and cone function in healthy people and people with retinal disease. They want to know if how well a person sees in the dark can test the severity of retinal disease.

Objectives:

To find out if how well a person sees in the dark can…

NCT04439708 — Biomarkers and Choroidal Neovascularization

StatusRecruiting
PhaseN/A
SponsorInstitut National de la Santé Et de la Recherche Médicale, France
Enrollment250
Study TypeOBSERVATIONAL
ConditionsChoroidal Neovascularization; Mineralocorticoid Excess
Interventions

The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.

NCT03848663 — Visual Remapping to Aid Reading With Field Loss

StatusRecruiting
PhaseN/A
SponsorUniversity of Minnesota
Enrollment108
Study TypeINTERVENTIONAL
ConditionsAge-related Macular Degeneration
Interventions;

Reading performance in patients with Central Vision Loss and age matched controls with artificial scotomas will be measured with and without different kinds of remapping of missing text to different parts of the visual field.

NCT05463289 — ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2

StatusRecruiting
PhaseN/A
SponsorJohns Hopkins University
Enrollment500
Study TypeINTERVENTIONAL
ConditionsType 1 Diabetes; Type 2 Diabetes; Cystic Fibrosis-related Diabetes
Interventions

The purpose of this study is to determine if use of a nonmydriatic fundus camera using autonomous artificial intelligence software at the point of care increases the proportion of underserved youth with diabetes screened for diabetic retinopathy, and to determine the diagnostic accuracy of the autonomous AI system in detecting diabetic retinopathy from retinal images of youth with diabetes.

NCT05726058 — Ocular Blood Flow Imaging for Glaucoma Assessment

StatusRecruiting
PhaseN/A
SponsorUniversity of Maryland, Baltimore
Enrollment150
Study TypeINTERVENTIONAL
ConditionsGlaucoma
Interventions

The goal of this clinical trial is to investigate the use of an FDA-cleared retinal blood flow imaging instrument called the XyCAM RI and XyCAM FC (Vasoptic Medical, Inc., Columbia, MD) in glaucoma management.

The main question it aims to answer are:

  • Can the investigators use blood flow to discriminate between eyes with early-stage glaucoma and variable-matched controls?
  • Can the investiga…

NCT06237127 — Effects of Goji vs. Fiber on Macular Degeneration

StatusRecruiting
PhaseN/A
SponsorUniversity of California, Davis
Enrollment60
Study TypeINTERVENTIONAL
ConditionsAge-Related Macular Degeneration
Interventions;

The goal of this project is to conduct a clinical trial in 60 participants ranging from age 65-95 who are at risk for age-related macular degeneration (AMD). The study will evaluate the effects of 14g of goji berry intake or an equivalent amount and type of fiber, five days a week for six months, on visual health, gut microbiome profiles, skin carotenoid measures, and lipoprotein profiles.

StatusRecruiting
PhasePhase 2
SponsorJanssen Research & Development, LLC
Enrollment274
Study TypeINTERVENTIONAL
ConditionsGeographic Atrophy; Macular Degeneration
Interventions;

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.

NCT06701721 — A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.

StatusRecruiting
PhasePhase 1
SponsorTherini Bio Pty Ltd
Enrollment21
Study TypeINTERVENTIONAL
ConditionsDiabetic Macular Edema; Diabetic Retinopathy
Interventions

THN391-OPT-101 is a study assessing safety and preliminary efficacy of THN391 in patients with diabetic macular edema (DME) given as monotherapy.

NCT06779773 — A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

StatusRecruiting
PhaseN/A
SponsorAstellas Pharma Global Development, Inc.
Enrollment500
Study TypeOBSERVATIONAL
ConditionsGeographic Atrophy; Macular Degeneration
Interventions

This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person’s central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of…

NCT06789445 — A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

StatusRecruiting
PhasePhase 1 / Phase 2
SponsorBlueRock Therapeutics
Enrollment54
Study TypeINTERVENTIONAL
ConditionsPrimary Photoreceptor Disease; Retinitis Pigmentosa (RP); Usher Syndrome; Inherited Retinal Disease (IRD); Rod-Cone Dystrophy
Interventions;

Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 focuses on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 o…

NCT07680244 — (CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000

StatusRecruiting
PhaseN/A
SponsorCarl Zeiss Meditec-Dublin CoCe
Enrollment400
Study TypeINTERVENTIONAL
ConditionsEpiretinal Membrane; Dry Age Related Macular Degeneration; Macular Abnormalities; Retina Disease; Vitreoretinal Abnormality
Interventions

This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.

StatusRecruiting
PhasePhase 1 / Phase 2
SponsorSanofi
Enrollment104
Study TypeINTERVENTIONAL
ConditionsGeographic Atrophy
Interventions;

This is a sequential Phase 1/2, two-part, multicenter study on safety, tolerability, and efficacy of one-time intravitreal SAR446597 for the treatment of participants with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).

The core phase duration will be approximately 2 years for each participant. An Extended Follow-Up (EFU) phase of 3 years follows the core phase.

T…

NCT07146516 — Retinal Detachment Prevention (Laser Prophylaxis) in Stickler Syndrome (SS)

StatusRecruiting
PhaseN/A
SponsorHelen Keller Eye Research Foundation
Enrollment500
Study TypeINTERVENTIONAL
ConditionsStickler Syndrome Type 1; Stickler Syndrome Type 2
Interventions

The goal of this clinical trial is to prospectively document to what extent the OSC/SS prophylactic laser retinopexy procedure works to prevent retinal detachment in SS in children and adults.

Researchers will compare the OSC/SS procedure in SS to the natural progression of SS to see to what extent the OSC/SS procedure works to prevent retinal detachment.

Participants will:

  • Have the OSC/SS…

NCT07354477 — Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

StatusRecruiting
PhasePhase 2
SponsorQlaris Bio, Inc.
Enrollment14
Study TypeINTERVENTIONAL
ConditionsNon-proliferative Diabetic Retinopathy (NPDR); Open-angle Glaucoma (OAG); Normal Tension Glaucoma (NTG)
Interventions;

Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG

StatusRecruiting
PhasePhase 1 / Phase 2
SponsorEyconis INC.
Enrollment30
Study TypeINTERVENTIONAL
ConditionsNeovascular (Wet) Age-Related Macular Degeneration
Interventions

This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.

NCT07419334 — Study of ALK-001 on the Progression of Stargardt Disease

StatusRecruiting
PhasePhase 3
SponsorAlkeus Pharmaceuticals, Inc.
Enrollment230
Study TypeINTERVENTIONAL
ConditionsStargardt Disease
Interventions;

This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)

NCT07592273 — Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

StatusRecruiting
PhasePhase 2 / Phase 3
SponsorAbbVie
Enrollment576
Study TypeINTERVENTIONAL
ConditionsDiabetic Retinopathy
Interventions; ;

Diabetic Retinopathy (DR) is a common eye condition caused by diabetes, where high blood sugar levels damage the blood vessels in the back part of the eye (called the retina). Over time, this damage can lead to vision problems and even blindness if not treated. This study will assess surabgene lomparvovec (sura-vec) as a potential one-time gene therapy administered in the suprachoroidal space (…

NCT07341763 — Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment

StatusRecruiting
PhaseN/A
SponsorUniversity of Waterloo
Enrollment20
Study TypeINTERVENTIONAL
ConditionsRetinitis Pigmentosa (RP); Rod Cone Dystrophy; Visually Impaired Persons; Peripheral Visual Field Defect of Both Eyes; Low Vision, Both Eyes
Interventions;

This pilot clinical trial evaluates whether non-invasive brain stimulation improves the orientation and mobility (O&M) skills of individuals with constricted visual fields in both eyes. The study is composed of three visits. The first visit is meant to confirm eligibility by performing a few clinical tests. Eligible participants will then complete two additional visits, one in which the partic…

NCT04401982 — Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects

StatusRecruiting
PhasePhase 4
SponsorUniversity of Maryland, Baltimore
Enrollment50
Study TypeINTERVENTIONAL
ConditionsOcular Hypertension; Suspect Glaucoma
Interventions;

The goal of this clinical trial is to compare participants treated with latanoprost to those treated with Rocklatan (netarsudil/latanoprost) to determine whether the addition of netarsudil results in greater improvements in episcleral venous blood flow in adults with glaucoma or ocular hypertension. Episcleral venous blood flow will be measured using erythrocyte-mediated angiography (EMA) and l…

Active, Not Recruiting

StatusActive, not recruiting
PhaseN/A
SponsorNational Eye Institute (NEI)
Enrollment110
Study TypeOBSERVATIONAL
ConditionsAge-Related Macular Degeneration; Cataract

This study is a 5-year extension of the AREDS protocol, in which investigators followed the natural course of age-related macular degeneration (AMD) and cataracts. Participants in the former AREDS protocol are eligible for this study.

Participants have a complete eye examination once a year and are contacted at least once a year between visits to check on their status. The eye examination incl…

StatusActive, not recruiting
PhaseN/A
SponsorNational Eye Institute (NEI)
Enrollment68
Study TypeOBSERVATIONAL
ConditionsRetinal Degeneration; ABCA4-Related Retinopathies

Background:

- The ABCA4 gene contains a blueprint for the ABCA4 protein. When this protein is absent or faulty (such as in Stargardt s disease), waste material from dead cells collects in the eye. The waste material may cause other cells in the eye to die. This can lead to the loss of vision. Researchers want to look at blood and skin samples from people with ABCA4 gene mutations to study rel…

NCT03655223 — Early Check: Expanded Screening in Newborns

StatusActive, not recruiting
PhaseN/A
SponsorRTI International
Enrollment30000
Study TypeOBSERVATIONAL
ConditionsSpinal Muscular Atrophy; Fragile X Syndrome; Fragile X - Premutation; Duchenne Muscular Dystrophy; Hyperinsulinemic Hypoglycemia, Familial 1
Interventions

Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and families who screen positive, and 3) evaluate the Early Check program. The Early Check screening will lead to earlier identification of newborns with rare health condi…

NCT03944239 — Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa

StatusActive, not recruiting
PhasePhase 1
SponsorQi Zhou
Enrollment25
Study TypeINTERVENTIONAL
ConditionsRetinitis Pigmentosa
Interventions

This project intends to transplant a clinical level human embryonic stem cells derived retinal pigment epithelium into subretinal space to treat eetinitis pigmentosa(RP) diseases. Through the statistical analysis EDTRS, BCVA, OCT, ERG, Fluorescein angiography, Ophthalmic AB ultrasound changes between before and after the treatment to assess the efficacy and safety 0f RPE transplants to treat RP…

NCT05705258 — A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)

StatusActive, not recruiting
PhaseN/A
SponsorBayer
Enrollment75
Study TypeOBSERVATIONAL
ConditionsRetinopathy of Prematurity; Newborns; Infants
Interventions

This is an observational study to collect data from Japanese babies with retinopathy of prematurity (ROP) who will be treated with Eylea. In observational studies, only observations are made without specified advice or interventions.

ROP is a condition that affects the eye and occurs only in babies who are born too early. Most cases of ROP are mild and get better without treatment, but more se…

NCT05957276 — Global Patient Registry of Inherited Retinal Diseases

StatusActive, not recruiting
PhaseN/A
SponsorJanssen Research & Development, LLC
Enrollment888
Study TypeOBSERVATIONAL
ConditionsInherited Retinal Diseases
Interventions

The purpose of this study is to better understand the natural history of Inherited Retinal Disease (IRD) and help inform patient management.

NCT05926583 — A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

StatusActive, not recruiting
PhasePhase 3
SponsorJanssen Pharmaceutical K.K.
Enrollment4
Study TypeINTERVENTIONAL
ConditionsRetinitis Pigmentosa
Interventions;

The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter. retinitis pigmentosa guanosine triphosphatase regulator (AAV5-hRKp.RPGR).

NCT06321302 — A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

StatusActive, not recruiting
PhasePhase 2
SponsorBoehringer Ingelheim
Enrollment190
Study TypeINTERVENTIONAL
ConditionsDiabetic Retinopathy
Interventions; ;

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study.

The purpose of this study is to find out whether a medicine called BI 764524 helps people with diabetic retinopathy. The study also aims to find a suitable treatment plan for BI 764524. Participants are put into 5 groups by chance. Part…

NCT07341919 — Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases

StatusActive, not recruiting
PhasePhase 1 / Phase 2
SponsorRubens Camargo Siqueira
Enrollment30
Study TypeINTERVENTIONAL
ConditionsExtensive Macular Atrophy With Pseudodrusen (EMAP); Retinitis Pigmentosa (RP)
Interventions

his prospective, comparative pilot study investigates the safety and functional outcomes of subtenon autologous platelet-rich plasma (PRP) in patients with Retinitis Pigmentosa (RP) and Extensive Macular Atrophy with Pseudodrusen-like Appearance (EMAP).

Participants will receive three subtenon injections of autologous platelet-rich plasma (1.5 mL per injection) administered at two-month interv…

StatusActive, not recruiting
PhasePhase 4
SponsorAstellas Pharma Inc
Enrollment17
Study TypeINTERVENTIONAL
ConditionsGeographic Atrophy; Age-Related Macular Degeneration
Interventions

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their vision over time. AMD damages the macula, which is in the middle of the retina - the light sensitive part at the back of the eye. In AMD, the cells in the macula die over time, usually over several years, leading to vision loss. When AMD gets worse, it can turn into either geographic atrophy (GA), neovasc…

Not Yet Recruiting

NCT07690436 — Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

StatusNot yet recruiting
PhaseN/A
SponsorAstraZeneca
Enrollment500
Study TypeOBSERVATIONAL
ConditionsTransthyretin Amyloid Cardiomyopathy

This multicenter pilot study will enroll adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure (HF) controls with documentation within the past 2 years that either excludes ATTR-CM or indicates a low probability of ATTR-CM. Ocular imaging and other study data will be collected to assess the feasibility of developing and prelim…

NCT07240649 — Emerging Indications for Hyperbaric Oxygen Treatment

StatusNot yet recruiting
PhasePhase 4
SponsorJay C. Buckey Jr.
Enrollment100
Study TypeINTERVENTIONAL
ConditionsPost-COVID-19 Condition; Ulcerative Colitis; Crohn Disease; Calciphylaxis; Frostbite
Interventions;

This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The re…

NCT07681778 — Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD)

StatusNot yet recruiting
PhasePhase 1 / Phase 2
SponsorOpus Genetics, Inc
Enrollment10
Study TypeINTERVENTIONAL
ConditionsLeber Congenital Amaurosis; Leber Congenital Amaurosis (LCA); LCA5
Interventions

This study is an early-stage clinical trial (Phase 1b/2a) testing a gene therapy called OPGx-RDH12 for people with Leber Congenital Amaurosis (LCA) caused by mutations in the RDH12 gene, a rare genetic eye disease that leads to severe vision loss. The treatment is delivered as a one-time injection (300 µL) into the retina (subretinal space) of the worse-seeing eye, using a method similar to app…

NCT07685886 — MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes

StatusNot yet recruiting
PhasePhase 4
SponsorUniversity of Colorado, Denver
Enrollment110
Study TypeINTERVENTIONAL
ConditionsDiabetes; Kidney Disease; Vascular Disease; Retinopathy
Interventions;

Diabetes mellitus type 2 is associated with significant morbidity and mortality; and identifying new treatments for diabetes complications to be used alone or in combination with other therapies is a high priority. Hyperglycemia triggers proinflammatory pathways leading to damage in the kidneys, eyes and blood vessels; thus targeting proinflammatory lipid mediators called leukotrienes may repre…

NCT06425419 — The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy

StatusNot yet recruiting
PhasePhase 1
SponsorMassachusetts Eye and Ear Infirmary
Enrollment50
Study TypeINTERVENTIONAL
ConditionsProliferative Vitreoretinopathy; Proliferative Vitreo-Retinopathy; Rhegmatogenous Retinal Detachment
Interventions

The goal of this clinical trial is to evaluate the safety and efficacy of intravitreal topotecan for the treatment of patients with rhegmatogenous retinal detachment due to proliferative vitreoretinopathy (PVR) or resulting from an open globe injury, and compare the outcomes to those who do no receive intravitreal topotecan. The main objectives it aims to achieve are:

  • to study the safety pro…

NCT07681167 — Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial

StatusNot yet recruiting
PhasePhase 2
SponsorSingapore National Eye Centre
Enrollment50
Study TypeINTERVENTIONAL
ConditionsCentral Serous Chorioretinopathy (CSC)
Interventions;

Dysregulation of the Angiopoietin-2 (Ang-2)/Tyrosine kinase with Immunoglobulin-like and EGF-like domains 2 (Tie-2) signaling pathway has been implicated in choroidal vascular instability and RPE dysfunction in Central serous chorioretinopathy (CSCR) and pachychoroid-associated neovascularization.

This study prospectively evaluates the efficacy and safety of faricimab compared to sham in CSCR …

NCT07290530 — 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

StatusNot yet recruiting
PhasePhase 3
SponsorNacuity Pharmaceuticals, Inc.
Enrollment80
Study TypeINTERVENTIONAL
ConditionsRetinitis Pigmentosa (RP); Usher Syndrome
Interventions;

The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are:

Does NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI…

NCT07216924 — Remapping Text in Sentence and Word Tasks to Aid Reading With Central Vision Loss

StatusNot yet recruiting
PhaseN/A
SponsorUniversity of Minnesota
Enrollment100
Study TypeINTERVENTIONAL
ConditionsMacular Degeneration; Central Visual Impairment
Interventions; ;

Reading performance in patients with Central Vision Loss will be measured with and without missing text being remapped to different parts of the visual field in a variety of different reading tasks.

Enrolling by Invitation

NCT07682025 — Imaging and Predictive Modelling of Proliferative Vitreoretinopathy.

StatusEnrolling by invitation
PhaseN/A
SponsorUniversity College, London
Enrollment100
Study TypeOBSERVATIONAL
ConditionsProliferative Vitreoretinopathy

Patients with retinal detachment are at risk of recurrence and failure of surgery requiring multiple surgeries due to a condition called proliferative vitreoretinopathy (PVR).

Study aims to help tailor patients’ treatments and improve outcomes by:

[i] studying imaging biomarkers of PVR, and [ii] develop AI models for PVR detection.

Inclusion:

  • Patients with ‘complicated’ retinal detach…

Completed Trials

NCT00055029 — Clinical and Genetic Studies of X-Linked Juvenile Retinoschisis

StatusCompleted
PhaseN/A
SponsorNational Eye Institute (NEI)
Enrollment351
Study TypeOBSERVATIONAL
ConditionsRetinoschisis

This study will explore the causes and eye problems of X-linked juvenile retinoschisis (XLRS), an inherited disease that causes vision loss primarily in young males. The vision loss, which worsens over time, is a result of schisis, or splitting, of the layers of the retina (tissue that lines the back of the eye). A better understanding of why and how XLRS develops might lead to improved treatme…

StatusCompleted
PhaseN/A
SponsorNational Eye Institute (NEI)
Enrollment217
Study TypeOBSERVATIONAL
ConditionsAge-Related Macular Degeneration

Background:

  • Age-related macular degeneration (AMD) is a leading cause of vision loss in individuals over 55 years of age. It can cause permanent loss of central vision, which is important for seeing fine details and long distances. AMD has two forms: wet AMD and dry AMD. Most people with AMD have dry AMD. But dry AMD can progress to wet AMD. Wet AMD is the more serious form and can result in…

NCT02210130 — The Microvascular Brain Retina And Kidney Study

StatusCompleted
PhaseN/A
SponsorFondation Ophtalmologique Adolphe de Rothschild
Enrollment163
Study TypeOBSERVATIONAL
ConditionsCerebral Small Vessels Disease

Cerebral small vessel disease (CSVD) is a major cause of cognitive impairment and disability in the general population, secondary to the accumulation of asymptomatic elementary lesions. CSVD is directly correlated with age and cardiovascular risk factors and therefore would be challenging in term of public health care in the future. While HIV patients share the same cardiovascular risk factors …

NCT03584165 — Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa

StatusCompleted
PhasePhase 3
SponsorNightstaRx Ltd, a Biogen Company
Enrollment277
Study TypeINTERVENTIONAL
ConditionsChoroideremia; X-Linked Retinitis Pigmentosa
Interventions;

The objective of the study is to evaluate the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111 and who have exited an antecedent study; these treated participants will be compared with untreated control participants who have exited the STAR (NCT03496012) study and BIIB112 in participants wi…

NCT04355689 — Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome

StatusCompleted
PhasePhase 1 / Phase 2
SponsorNacuity Pharmaceuticals, Inc.
Enrollment49
Study TypeINTERVENTIONAL
ConditionsUsher Syndromes
Interventions;

This study will examine the safety and efficacy of NPI-001 Tablets as compared to placebo for 24 months in subjects with vision loss due to RP associated with Usher syndrome.

NCT04505566 — INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study

StatusCompleted
PhasePhase 1
SponsorStephen J. Kim, MD
Enrollment164
Study TypeINTERVENTIONAL
ConditionsDiabetic Retinopathy
Interventions; ;

The central hypothesis is that inflammation mediators are biomarkers of both systemic diabetes and Diabetic Retinopathy (DR) progression in the aqueous and that sustained topical ketorolac application reduces/suppresses those inflammatory mediators thereby reducing the progression of Diabetic Retinopathy.

NCT06164587 — Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy

StatusCompleted
PhasePhase 1 / Phase 2
SponsorMichelle Abou-Jaoude
Enrollment30
Study TypeINTERVENTIONAL
ConditionsGeographic Atrophy; Age-Related Macular Degeneration
Interventions

This interventional study is a single-center, open label, 26-week study, designed to evaluate the safety and treatment efficacy of K8 in patients with geographic atrophy (GA) due to age-related macular degeneration (AMD). Up to 5 subjects will receive study medication. Study treatment will be administered by intravitreal injections. Number of participants has been expanded to 30.

Participants …

NCT07690800 — Outcomes of Intravitreal Ranibizumab Injection for Diabetic Vitreous Hemorrhage

StatusCompleted
PhasePhase 4
SponsorBenha University
Enrollment30
Study TypeINTERVENTIONAL
ConditionsDiabetic Vitreous Hemorrhage; Intravitreal Injections; Ranibizumab
Interventions

This prospective interventional cohort study evaluates the outcomes of intravitreal ranibizumab injection in patients with diabetic vitreous hemorrhage secondary to proliferative diabetic retinopathy. The study aims to assess the effectiveness of ranibizumab in improving visual acuity, promoting vitreous hemorrhage clearance, reducing the need for pars plana vitrectomy, and evaluating treatment…

Other (Suspended)

NCT01878045 — Mechanisms of Diabetic Kidney Disease in American Indians

StatusSuspended
PhaseN/A
SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrollment141
Study TypeOBSERVATIONAL
ConditionsNervous System; Diabetic Kidney Disease; Diabetes Mellitus, Type 2

Background:

- An ongoing study is looking at American Indians who have kidney problems caused by type 2 diabetes. Kidney disease due to type 2 diabetes is a major problem in American Indians. We previously found that early treatment of kidney disease with losartan was probably beneficial for reducing progression of the disease. Researchers now want to see if these benefits continue to be seen…

Other (Terminated)

NCT04699864 — Evaluation of NeoRetina Artificial Intelligence Algorithm for the Screening of Diabetic Retinopathy at the CHUM

StatusTerminated
PhaseN/A
SponsorCentre hospitalier de l’Université de Montréal (CHUM)
Enrollment24
Study TypeINTERVENTIONAL
ConditionsDiabetic Retinopathy; Diabetic Macular Edema; Diabetic Maculopathy
Interventions; ;

This prospective study aims to validate if NeoRetina, an artificial intelligence algorithm developped by DIAGNOS Inc. and trained to automatically detect the presence of diabetic retinopathy (DR) by the analysis of macula centered eye fundus photographies, can detect this disease and grade its severity.